On October 31, 2016 Deciphera Pharmaceuticals, a clinical-stage biotechnology company focused on developing tumor-targeted and immuno-targeted advanced kinase inhibitors, reported that two abstracts featuring the Company’s clinical-stage tumor-targeted therapies have been selected for a late-breaking oral presentation and a poster discussion at the 28th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics taking place November 29 to December 2, 2016 in Munich, Germay (Press release, Deciphera Pharmaceuticals, OCT 31, 2016, View Source [SID1234516122]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
DCC-2618 is a pan-KIT and PDGFR kinase inhibitor in clinical development for the treatment of genetically-defined cancers, including gastrointestinal stromal tumors (GIST) and other KIT-driven cancers such as systemic mastocytosis. Altiratinib is a spectrum selective inhibitor of MET, TRK, TIE2 & VEGFR2 kinases in clinical development for the treatment of solid tumors. DCC-2618 and altiratinib are both currently in Phase 1 first-in-human studies.
"Genetically-defined cancers with specific kinase mutations, such as gastrointestinal stromal tumors and systemic mastocytosis, are ideal targets for our advanced kinase inhibitors and we look forward to sharing clinical data on DCC-2618 and altiratinib at the upcoming EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics," stated Michael D. Taylor, Ph.D., President and Chief Executive Officer of Deciphera Pharmaceuticals.
Late-breaking Oral Presentation:
Title: DCC-2618, a pan KIT and PDGFR switch control inhibitor, achieves proof-of-concept
in a first-in-human study
Author: Janku, F., MD Anderson Cancer Center
Abstract: 7LBA
Session: Plenary Session 6: Proffered Paper Session
Date/Time: Thursday, December 1, 2016, 4:10 p.m. (CET)
Poster Presentation:
Title: The type II switch control kinase inhibitor, DCC-2701 (altiratinib) effectively inhibits
resistant NTRK kinase domain mutants
Author: Drilon, A.
Abstract/Board: 422/P101
Session: Poster Session: Molecular targeted agents II
Date/Time: Thursday, December 1, 2016, 10:15 a.m. – 5:00 p.m. (CET)